EMERYVILLE, Calif.,
April 7, 2021 /PRNewswire/ -- Amyris,
Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology
company active in the Clean Health and Beauty markets through its
consumer brands and a top supplier of sustainable and natural
ingredients, today announced the commencement of a proposed
underwritten public offering of shares of its common stock.
Amyris is conducting a resale of stock on behalf of its current
stockholders, DSM International B.V. and affiliates of Vivo Capital
LLC (the selling stockholders). The selling stockholders intend to
offer an aggregate of $150.0 million
of shares of Amyris's common stock. Amyris will not receive any
proceeds from the sale of the shares by the selling stockholders.
Additionally, Amyris intends to offer $100.0
million of shares of its common stock to support its
continued growth.
The selling stockholders and Amyris expect to grant the
underwriters a 30-day option to purchase up to an additional
$37.5 million of shares of Amyris's
common stock at the public offering price, less underwriting
discounts and commissions. The proposed offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
J.P. Morgan Securities LLC and Cowen and Company, LLC are acting
as the joint bookrunning managers for the proposed offering.
The public offering is being made pursuant to an automatic shelf
registration statement on Form S-3 that was filed by Amyris with
the U.S. Securities and Exchange Commission (the "SEC") and
automatically became effective upon filing. The proposed offering
is being made only by means of an effective shelf registration
statement, including a preliminary prospectus and final prospectus,
copies of which may be obtained, when available, from J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717,
by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; or Cowen and Company, LLC, c/o
Broadridge Financial Solutions, Attn: Prospectus Department, 1155
Long Island Avenue, Edgewood, NY
11717, by telephone at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Amyris
Amyris (Nasdaq: AMRS) is a science and technology leader in the
research, development and production of sustainable ingredients for
the Clean Health & Beauty and Flavors & Fragrances markets.
Amyris uses an impressive array of exclusive technologies,
including state-of-the-art machine learning, robotics and
artificial intelligence. Our ingredients are included in over 3,000
products from the world's top brands, reaching more than 200
million consumers. Amyris is proud to own three consumer brands -
all built around its No Compromise® promise of clean ingredients:
Biossance® clean beauty skincare, Pipette® clean baby skincare and
Purecane™, a zero-calorie sweetener naturally derived from
sugarcane. Amyris, the Amyris logo, No Compromise, Biossance,
Pipette, and Purecane are trademarks or registered trademarks of
Amyris, Inc. in the U.S. and/or other countries.
Use of forward-looking statements
This press release contains "forward-looking statements" within
the meaning of, and made pursuant to the Securities Act of 1933, as
amended, the Securities Exchange Act of 1934, as amended, and safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
terms of the proposed public offering, including the selling
stockholders' and our expectations with respect to granting the
underwriters a 30-day option to purchase additional shares, and the
completion, timing, size and dilutive impact of the proposed public
offering. These forward-looking statements may be accompanied by
such words as "aim," "anticipate," "believe," "could," "estimate,"
"expect," "forecast," "goal," "intend," "may," "might," "plan,"
"potential," "possible," "will," "would," and other words and terms
of similar meaning. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected our public filings, including without
limitation, risks which are outside of our full control; risks
associated with current and potential delays, work stoppages, or
supply chain disruptions caused by the coronavirus pandemic; and
the other risks and uncertainties that are described in the Risk
Factors section in our Annual Report on Form 10-K filed with
the SEC on March 5, 2021, and other
reports as filed with the SEC, the preliminary prospectus
supplement related to the proposed public offering and subsequent
filings with the SEC. We undertake no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amyris-announces-proposed-public-offering-secondary-and-primary-of-common-stock-301264570.html
SOURCE Amyris, Inc.